#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Results and Discussion
2-1	4-11	Results	abstract	new	_	_
2-2	12-15	and	_	_	_	_
2-3	16-26	Discussion	abstract	new	_	_

#Text=During the drug design process , to assess the potential druggability of a compound as a new starting point , some initial rules like drug-likeness ( as defined by Lipinski and colleagues in 1997 ) , lead-likeness ( as defined by Oprea ) and known drug space , are usually applied .
3-1	27-33	During	_	_	_	_
3-2	34-37	the	event[6]	new[6]	_	_
3-3	38-42	drug	substance|event[6]	new|new[6]	coref	3-46
3-4	43-49	design	abstract|event[6]	new|new[6]	_	_
3-5	50-57	process	event[6]	new[6]	_	_
3-6	58-59	,	_	_	_	_
3-7	60-62	to	_	_	_	_
3-8	63-69	assess	_	_	_	_
3-9	70-73	the	abstract[7]	new[7]	_	_
3-10	74-83	potential	abstract[7]	new[7]	_	_
3-11	84-96	druggability	abstract[7]	new[7]	_	_
3-12	97-99	of	abstract[7]	new[7]	_	_
3-13	100-101	a	abstract[7]|abstract[8]	new[7]|new[8]	coref	4-8[0_8]
3-14	102-110	compound	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-15	111-113	as	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-16	114-115	a	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-17	116-119	new	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-18	120-128	starting	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-19	129-134	point	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-20	135-136	,	_	_	_	_
3-21	137-141	some	abstract[9]	new[9]	coref	4-4[19_9]
3-22	142-149	initial	abstract[9]	new[9]	_	_
3-23	150-155	rules	abstract[9]	new[9]	_	_
3-24	156-160	like	abstract[9]	new[9]	_	_
3-25	161-174	drug-likeness	abstract[9]|abstract	new[9]|new	_	_
3-26	175-176	(	_	_	_	_
3-27	177-179	as	_	_	_	_
3-28	180-187	defined	_	_	_	_
3-29	188-190	by	_	_	_	_
3-30	191-199	Lipinski	person	new	_	_
3-31	200-203	and	_	_	_	_
3-32	204-214	colleagues	person	new	_	_
3-33	215-217	in	_	_	_	_
3-34	218-222	1997	time	new	_	_
3-35	223-224	)	_	_	_	_
3-36	225-226	,	_	_	_	_
3-37	227-240	lead-likeness	substance	new	_	_
3-38	241-242	(	_	_	_	_
3-39	243-245	as	_	_	_	_
3-40	246-253	defined	_	_	_	_
3-41	254-256	by	_	_	_	_
3-42	257-262	Oprea	person	new	_	_
3-43	263-264	)	_	_	_	_
3-44	265-268	and	_	_	_	_
3-45	269-274	known	place[17]	new[17]	coref	5-19[37_17]
3-46	275-279	drug	substance|place[17]	giv|new[17]	_	_
3-47	280-285	space	place[17]	new[17]	_	_
3-48	286-287	,	_	_	_	_
3-49	288-291	are	_	_	_	_
3-50	292-299	usually	_	_	_	_
3-51	300-307	applied	_	_	_	_
3-52	308-309	.	_	_	_	_

#Text=In general , the rules to characterise/filter compound collections are based upon physicochemical parameters , e. g. , logP , logS , MW , TPSA , MR , RotN , HBA and HBD , among others .
4-1	310-312	In	_	_	_	_
4-2	313-320	general	person	new	_	_
4-3	321-322	,	_	_	_	_
4-4	323-326	the	abstract[19]	giv[19]	coref	7-15[54_19]
4-5	327-332	rules	abstract[19]	giv[19]	_	_
4-6	333-335	to	abstract[19]	giv[19]	_	_
4-7	336-355	characterise/filter	abstract[19]|abstract[21]	giv[19]|new[21]	_	_
4-8	356-364	compound	abstract[19]|abstract|abstract[21]	giv[19]|giv|new[21]	coref	23-27
4-9	365-376	collections	abstract[19]|abstract[21]	giv[19]|new[21]	_	_
4-10	377-380	are	_	_	_	_
4-11	381-386	based	_	_	_	_
4-12	387-391	upon	_	_	_	_
4-13	392-407	physicochemical	abstract[22]	new[22]	_	_
4-14	408-418	parameters	abstract[22]	new[22]	_	_
4-15	419-420	,	_	_	_	_
4-16	421-423	e.	_	_	_	_
4-17	424-426	g.	_	_	_	_
4-18	427-428	,	_	_	_	_
4-19	429-433	logP	abstract	new	_	_
4-20	434-435	,	_	_	_	_
4-21	436-440	logS	abstract	new	_	_
4-22	441-442	,	_	_	_	_
4-23	443-445	MW	abstract	new	_	_
4-24	446-447	,	_	_	_	_
4-25	448-452	TPSA	abstract	new	_	_
4-26	453-454	,	_	_	_	_
4-27	455-457	MR	abstract	new	_	_
4-28	458-459	,	_	_	_	_
4-29	460-464	RotN	abstract	new	_	_
4-30	465-466	,	_	_	_	_
4-31	467-470	HBA	abstract	new	_	_
4-32	471-474	and	_	_	_	_
4-33	475-478	HBD	abstract	new	_	_
4-34	479-480	,	_	_	_	_
4-35	481-486	among	_	_	_	_
4-36	487-493	others	_	_	_	_
4-37	494-495	.	_	_	_	_

#Text=As a result , it would be interesting to assess how proteasome inhibitors are positioned with respect to the typically expected “ drug-like ” chemical space .
5-1	496-498	As	_	_	_	_
5-2	499-500	a	abstract[31]	new[31]	_	_
5-3	501-507	result	abstract[31]	new[31]	_	_
5-4	508-509	,	_	_	_	_
5-5	510-512	it	abstract	new	cata	5-5[0_33]
5-6	513-518	would	_	_	_	_
5-7	519-521	be	_	_	_	_
5-8	522-533	interesting	_	_	_	_
5-9	534-536	to	abstract[33]	new[33]	_	_
5-10	537-543	assess	abstract[33]	new[33]	_	_
5-11	544-547	how	abstract[33]	new[33]	_	_
5-12	548-558	proteasome	abstract[33]|abstract[34]	new[33]|new[34]	coref	6-15[0_34]
5-13	559-569	inhibitors	abstract[33]|abstract[34]	new[33]|new[34]	_	_
5-14	570-573	are	abstract[33]	new[33]	_	_
5-15	574-584	positioned	abstract[33]	new[33]	_	_
5-16	585-589	with	_	_	_	_
5-17	590-597	respect	abstract[35]	new[35]	_	_
5-18	598-600	to	abstract[35]	new[35]	_	_
5-19	601-604	the	abstract[35]|place[37]	new[35]|giv[37]	coref	7-6[0_37]
5-20	605-614	typically	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-21	615-623	expected	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-22	624-625	“	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-23	626-635	drug-like	abstract[35]|substance|place[37]	new[35]|new|giv[37]	_	_
5-24	636-637	”	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-25	638-646	chemical	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-26	647-652	space	abstract[35]|place[37]	new[35]|giv[37]	_	_
5-27	653-654	.	_	_	_	_

#Text=To do so , we performed a comprehensive analysis of the 680 small-molecules proteasome inhibitors dataset spanning a large range of activity ( 0.08 nM < IC50 ≤ 150,000 nM ) .
6-1	655-657	To	_	_	_	_
6-2	658-660	do	_	_	_	_
6-3	661-663	so	_	_	_	_
6-4	664-665	,	_	_	_	_
6-5	666-668	we	person	acc	ana	12-3
6-6	669-678	performed	_	_	_	_
6-7	679-680	a	abstract[39]	new[39]	coref	13-3[93_39]
6-8	681-694	comprehensive	abstract[39]	new[39]	_	_
6-9	695-703	analysis	abstract[39]	new[39]	_	_
6-10	704-706	of	abstract[39]	new[39]	_	_
6-11	707-710	the	abstract[39]|abstract[42]	new[39]|new[42]	coref	9-1[69_42]
6-12	711-714	680	abstract[39]|abstract[42]	new[39]|new[42]	_	_
6-13	715-730	small-molecules	abstract[39]|abstract|abstract[42]	new[39]|new|new[42]	_	_
6-14	731-741	proteasome	abstract[39]|abstract[42]	new[39]|new[42]	_	_
6-15	742-752	inhibitors	abstract[39]|abstract|abstract[42]	new[39]|giv|new[42]	coref	11-11[88_0]
6-16	753-760	dataset	abstract[39]|abstract[42]	new[39]|new[42]	_	_
6-17	761-769	spanning	_	_	_	_
6-18	770-771	a	abstract[43]	new[43]	_	_
6-19	772-777	large	abstract[43]	new[43]	_	_
6-20	778-783	range	abstract[43]	new[43]	_	_
6-21	784-786	of	abstract[43]	new[43]	_	_
6-22	787-795	activity	abstract[43]|abstract	new[43]|new	ana	7-1
6-23	796-797	(	_	_	_	_
6-24	798-802	0.08	quantity[45]	new[45]	_	_
6-25	803-805	nM	quantity[45]	new[45]	_	_
6-26	806-807	<	_	_	_	_
6-27	808-812	IC50	quantity	new	_	_
6-28	813-814	≤	_	_	_	_
6-29	815-822	150,000	quantity[47]	new[47]	_	_
6-30	823-825	nM	quantity[47]	new[47]	_	_
6-31	826-827	)	_	_	_	_
6-32	828-829	.	_	_	_	_

#Text=This entailed looking at chemical space distribution , scaffold similarity and the extraction of chemical rules with machine learning , using either direct structural information ( scaffolds and Morgan fingerprints ) or being based on 21 general molecular ( QuaSAR ) descriptors .
7-1	830-834	This	abstract	giv	coref	8-17[68_0]
7-2	835-843	entailed	_	_	_	_
7-3	844-851	looking	_	_	_	_
7-4	852-854	at	_	_	_	_
7-5	855-863	chemical	abstract[50]	new[50]	coref	11-3[84_50]
7-6	864-869	space	place|abstract[50]	giv|new[50]	coref	11-4
7-7	870-882	distribution	abstract[50]	new[50]	_	_
7-8	883-884	,	_	_	_	_
7-9	885-893	scaffold	quantity|abstract[52]	new|new[52]	coref|coref|coref|coref	11-8|11-7[86_52]|11-8|11-7[86_52]
7-10	894-904	similarity	abstract[52]	new[52]	_	_
7-11	905-908	and	_	_	_	_
7-12	909-912	the	abstract[53]	new[53]	_	_
7-13	913-923	extraction	abstract[53]	new[53]	_	_
7-14	924-926	of	abstract[53]	new[53]	_	_
7-15	927-935	chemical	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
7-16	936-941	rules	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
7-17	942-946	with	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
7-18	947-954	machine	abstract[53]|abstract[54]|abstract[55]	new[53]|giv[54]|new[55]	_	_
7-19	955-963	learning	abstract[53]|abstract[54]|abstract[55]	new[53]|giv[54]|new[55]	_	_
7-20	964-965	,	_	_	_	_
7-21	966-971	using	_	_	_	_
7-22	972-978	either	abstract[56]	new[56]	coref	13-23[98_56]
7-23	979-985	direct	abstract[56]	new[56]	_	_
7-24	986-996	structural	abstract[56]	new[56]	_	_
7-25	997-1008	information	abstract[56]	new[56]	_	_
7-26	1009-1010	(	_	_	_	_
7-27	1011-1020	scaffolds	object|object[58]	new|new[58]	coref|coref|coref|coref	25-10[176_0]|29-24[201_58]|25-10[176_0]|29-24[201_58]
7-28	1021-1024	and	object[58]	new[58]	_	_
7-29	1025-1031	Morgan	object[58]|person|object[60]	new[58]|new|new[60]	_	_
7-30	1032-1044	fingerprints	object[58]|object[60]	new[58]|new[60]	_	_
7-31	1045-1046	)	_	_	_	_
7-32	1047-1049	or	_	_	_	_
7-33	1050-1055	being	_	_	_	_
7-34	1056-1061	based	_	_	_	_
7-35	1062-1064	on	_	_	_	_
7-36	1065-1067	21	quantity[61]|abstract[63]	new[61]|new[63]	coref|coref	13-16[97_63]|13-16[97_63]
7-37	1068-1075	general	quantity[61]|abstract[63]	new[61]|new[63]	_	_
7-38	1076-1085	molecular	quantity[61]|abstract[63]	new[61]|new[63]	_	_
7-39	1086-1087	(	abstract[63]	new[63]	_	_
7-40	1088-1094	QuaSAR	abstract|abstract[63]	new|new[63]	_	_
7-41	1095-1096	)	abstract[63]	new[63]	_	_
7-42	1097-1108	descriptors	abstract[63]	new[63]	_	_
7-43	1109-1110	.	_	_	_	_

#Text=This set of analyses was ultimately employed to produce meaningful chemical patterns that are correlated with proteasome inhibitory activity .
8-1	1111-1115	This	abstract[64]	new[64]	_	_
8-2	1116-1119	set	abstract[64]	new[64]	_	_
8-3	1120-1122	of	abstract[64]	new[64]	_	_
8-4	1123-1131	analyses	abstract[64]|abstract	new[64]|new	_	_
8-5	1132-1135	was	_	_	_	_
8-6	1136-1146	ultimately	_	_	_	_
8-7	1147-1155	employed	_	_	_	_
8-8	1156-1158	to	_	_	_	_
8-9	1159-1166	produce	_	_	_	_
8-10	1167-1177	meaningful	abstract[66]	new[66]	_	_
8-11	1178-1186	chemical	abstract[66]	new[66]	_	_
8-12	1187-1195	patterns	abstract[66]	new[66]	_	_
8-13	1196-1200	that	_	_	_	_
8-14	1201-1204	are	_	_	_	_
8-15	1205-1215	correlated	_	_	_	_
8-16	1216-1220	with	_	_	_	_
8-17	1221-1231	proteasome	abstract[68]	giv[68]	coref	9-7[0_68]
8-18	1232-1242	inhibitory	abstract|abstract[68]	new|giv[68]	_	_
8-19	1243-1251	activity	abstract[68]	giv[68]	_	_
8-20	1252-1253	.	_	_	_	_

#Text=The dataset comprises only human proteasome activity data for the CT-L catalytic site , as this is the only site with the largest number of compounds , and is divided into four classes .
9-1	1254-1257	The	abstract[69]	giv[69]	coref	25-22[180_69]
9-2	1258-1265	dataset	abstract[69]	giv[69]	_	_
9-3	1266-1275	comprises	_	_	_	_
9-4	1276-1280	only	abstract[71]	new[71]	coref	10-1[79_71]
9-5	1281-1286	human	abstract[71]	new[71]	_	_
9-6	1287-1297	proteasome	abstract[71]	new[71]	_	_
9-7	1298-1306	activity	abstract|abstract[71]	giv|new[71]	coref	17-11
9-8	1307-1311	data	abstract[71]	new[71]	_	_
9-9	1312-1315	for	abstract[71]	new[71]	_	_
9-10	1316-1319	the	abstract[71]|place[73]	new[71]|new[73]	ana	9-16[0_73]
9-11	1320-1324	CT-L	abstract[71]|abstract|place[73]	new[71]|new|new[73]	_	_
9-12	1325-1334	catalytic	abstract[71]|place[73]	new[71]|new[73]	_	_
9-13	1335-1339	site	abstract[71]|place[73]	new[71]|new[73]	_	_
9-14	1340-1341	,	_	_	_	_
9-15	1342-1344	as	_	_	_	_
9-16	1345-1349	this	place	giv	coref	9-18[75_0]
9-17	1350-1352	is	_	_	_	_
9-18	1353-1356	the	place[75]	giv[75]	_	_
9-19	1357-1361	only	place[75]	giv[75]	_	_
9-20	1362-1366	site	place[75]	giv[75]	_	_
9-21	1367-1371	with	place[75]	giv[75]	_	_
9-22	1372-1375	the	place[75]|quantity[76]	giv[75]|new[76]	_	_
9-23	1376-1383	largest	place[75]|quantity[76]	giv[75]|new[76]	_	_
9-24	1384-1390	number	place[75]|quantity[76]	giv[75]|new[76]	_	_
9-25	1391-1393	of	place[75]|quantity[76]	giv[75]|new[76]	_	_
9-26	1394-1403	compounds	place[75]|quantity[76]|substance	giv[75]|new[76]|new	coref	17-18[116_0]
9-27	1404-1405	,	_	_	_	_
9-28	1406-1409	and	_	_	_	_
9-29	1410-1412	is	_	_	_	_
9-30	1413-1420	divided	_	_	_	_
9-31	1421-1425	into	_	_	_	_
9-32	1426-1430	four	person[78]	new[78]	coref	17-9[115_78]
9-33	1431-1438	classes	person[78]	new[78]	_	_
9-34	1439-1440	.	_	_	_	_

#Text=Full data are available in Table S1 .
10-1	1441-1445	Full	abstract[79]	giv[79]	_	_
10-2	1446-1450	data	abstract[79]	giv[79]	_	_
10-3	1451-1454	are	_	_	_	_
10-4	1455-1464	available	_	_	_	_
10-5	1465-1467	in	_	_	_	_
10-6	1468-1473	Table	abstract|object[81]	new|new[81]	coref|coref|coref|coref	13-27|13-27[100_81]|13-27|13-27[100_81]
10-7	1474-1476	S1	object[81]	new[81]	_	_
10-8	1477-1478	.	_	_	_	_

#Text=Analysis of chemical space distribution and the scaffold similarity of proteasome inhibitors .
11-1	1479-1487	Analysis	abstract[82]	new[82]	_	_
11-2	1488-1490	of	abstract[82]	new[82]	_	_
11-3	1491-1499	chemical	abstract[82]|abstract[84]	new[82]|giv[84]	coref	12-5[92_84]
11-4	1500-1505	space	abstract[82]|place|abstract[84]	new[82]|giv|giv[84]	coref	12-10
11-5	1506-1518	distribution	abstract[82]|abstract[84]	new[82]|giv[84]	_	_
11-6	1519-1522	and	abstract[82]	new[82]	_	_
11-7	1523-1526	the	abstract[82]|abstract[86]	new[82]|giv[86]	coref	23-11[160_86]
11-8	1527-1535	scaffold	abstract[82]|quantity|abstract[86]	new[82]|giv|giv[86]	_	_
11-9	1536-1546	similarity	abstract[82]|abstract[86]	new[82]|giv[86]	_	_
11-10	1547-1549	of	abstract[82]|abstract[86]	new[82]|giv[86]	_	_
11-11	1550-1560	proteasome	abstract[82]|abstract[86]|abstract|object[88]	new[82]|giv[86]|new|giv[88]	coref|coref	12-5[90_88]|12-5[90_88]
11-12	1561-1571	inhibitors	abstract[82]|abstract[86]|object[88]	new[82]|giv[86]|giv[88]	_	_
11-13	1572-1573	.	_	_	_	_

#Text=First , we analyzed human proteasome inhibitors ’ chemical space distribution .
12-1	1574-1579	First	_	_	_	_
12-2	1580-1581	,	_	_	_	_
12-3	1582-1584	we	person	giv	ana	22-34
12-4	1585-1593	analyzed	_	_	_	_
12-5	1594-1599	human	abstract[90]|abstract[92]	giv[90]|giv[92]	coref|coref	21-33[148_90]|21-33[148_90]
12-6	1600-1610	proteasome	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-7	1611-1621	inhibitors	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-8	1622-1623	’	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-9	1624-1632	chemical	abstract[92]	giv[92]	_	_
12-10	1633-1638	space	place|abstract[92]	giv|giv[92]	coref	13-6[94_0]
12-11	1639-1651	distribution	abstract[92]	giv[92]	_	_
12-12	1652-1653	.	_	_	_	_

#Text=To address this analysis , chemical space was defined by the t-SNE calculation applied to the 21 calculated molecular descriptors listed in the Supplementary Information ( Table S1 ) .
13-1	1654-1656	To	_	_	_	_
13-2	1657-1664	address	_	_	_	_
13-3	1665-1669	this	abstract[93]	giv[93]	_	_
13-4	1670-1678	analysis	abstract[93]	giv[93]	_	_
13-5	1679-1680	,	_	_	_	_
13-6	1681-1689	chemical	place[94]	giv[94]	coref	14-35[110_94]
13-7	1690-1695	space	place[94]	giv[94]	_	_
13-8	1696-1699	was	_	_	_	_
13-9	1700-1707	defined	_	_	_	_
13-10	1708-1710	by	_	_	_	_
13-11	1711-1714	the	abstract[96]	new[96]	_	_
13-12	1715-1720	t-SNE	abstract|abstract[96]	new|new[96]	_	_
13-13	1721-1732	calculation	abstract[96]	new[96]	_	_
13-14	1733-1740	applied	_	_	_	_
13-15	1741-1743	to	_	_	_	_
13-16	1744-1747	the	abstract[97]	giv[97]	coref	22-31[155_97]
13-17	1748-1750	21	abstract[97]	giv[97]	_	_
13-18	1751-1761	calculated	abstract[97]	giv[97]	_	_
13-19	1762-1771	molecular	abstract[97]	giv[97]	_	_
13-20	1772-1783	descriptors	abstract[97]	giv[97]	_	_
13-21	1784-1790	listed	_	_	_	_
13-22	1791-1793	in	_	_	_	_
13-23	1794-1797	the	abstract[98]	giv[98]	_	_
13-24	1798-1811	Supplementary	abstract[98]	giv[98]	_	_
13-25	1812-1823	Information	abstract[98]	giv[98]	_	_
13-26	1824-1825	(	_	_	_	_
13-27	1826-1831	Table	abstract|object[100]	giv|giv[100]	_	_
13-28	1832-1834	S1	object[100]	giv[100]	_	_
13-29	1835-1836	)	_	_	_	_
13-30	1837-1838	.	_	_	_	_

#Text=The proximity in a t-SNE plot is relative in nature , and the distance between points simply represents relative proximity ( i. e. , it is not a direct scaling from real distances in the 21 dimensional space ) .
14-1	1839-1842	The	abstract[101]	new[101]	coref	14-19[106_101]
14-2	1843-1852	proximity	abstract[101]	new[101]	_	_
14-3	1853-1855	in	abstract[101]	new[101]	_	_
14-4	1856-1857	a	abstract[101]|abstract[102]	new[101]|new[102]	coref	17-44[124_102]
14-5	1858-1863	t-SNE	abstract[101]|abstract[102]	new[101]|new[102]	_	_
14-6	1864-1868	plot	abstract[101]|abstract[102]	new[101]|new[102]	_	_
14-7	1869-1871	is	_	_	_	_
14-8	1872-1880	relative	_	_	_	_
14-9	1881-1883	in	_	_	_	_
14-10	1884-1890	nature	abstract	new	_	_
14-11	1891-1892	,	_	_	_	_
14-12	1893-1896	and	_	_	_	_
14-13	1897-1900	the	object[104]	new[104]	_	_
14-14	1901-1909	distance	object[104]	new[104]	_	_
14-15	1910-1917	between	object[104]	new[104]	_	_
14-16	1918-1924	points	object[104]|object	new[104]|new	_	_
14-17	1925-1931	simply	_	_	_	_
14-18	1932-1942	represents	_	_	_	_
14-19	1943-1951	relative	abstract[106]	giv[106]	ana	14-25[0_106]
14-20	1952-1961	proximity	abstract[106]	giv[106]	_	_
14-21	1962-1963	(	_	_	_	_
14-22	1964-1966	i.	_	_	_	_
14-23	1967-1969	e.	_	_	_	_
14-24	1970-1971	,	_	_	_	_
14-25	1972-1974	it	abstract	giv	_	_
14-26	1975-1977	is	_	_	_	_
14-27	1978-1981	not	_	_	_	_
14-28	1982-1983	a	abstract[108]	new[108]	_	_
14-29	1984-1990	direct	abstract[108]	new[108]	_	_
14-30	1991-1998	scaling	abstract[108]	new[108]	_	_
14-31	1999-2003	from	abstract[108]	new[108]	_	_
14-32	2004-2008	real	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-33	2009-2018	distances	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-34	2019-2021	in	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-35	2022-2025	the	abstract[108]|abstract[109]|place[110]	new[108]|new[109]|giv[110]	coref	22-21[153_110]
14-36	2026-2028	21	abstract[108]|abstract[109]|place[110]	new[108]|new[109]|giv[110]	_	_
14-37	2029-2040	dimensional	abstract[108]|abstract[109]|place[110]	new[108]|new[109]|giv[110]	_	_
14-38	2041-2046	space	abstract[108]|abstract[109]|place[110]	new[108]|new[109]|giv[110]	_	_
14-39	2047-2048	)	_	_	_	_
14-40	2049-2050	.	_	_	_	_

#Text=In
15-1	2051-2053	In	_	_	_	_

#Text=Figure 4
16-1	2054-2060	Figure	abstract[111]	new[111]	coref	18-1[132_111]
16-2	2061-2062	4	abstract[111]	new[111]	_	_

#Text=( left ) the difference of distribution of the four activity classes is easily perceptible , with the most active compounds ( class A , purple ) having close to half of its compounds ( ~47 % ) in the top-right quadrant of the plot , while the least active compounds ( class D , orange ) are mainly concentrated in the bottom-left quadrant ( ~58 % of class D compounds ) , as quantified in
17-1	2063-2064	(	_	_	_	_
17-2	2065-2069	left	_	_	_	_
17-3	2070-2071	)	_	_	_	_
17-4	2072-2075	the	abstract[112]	new[112]	_	_
17-5	2076-2086	difference	abstract[112]	new[112]	_	_
17-6	2087-2089	of	abstract[112]	new[112]	_	_
17-7	2090-2102	distribution	abstract[112]|abstract[113]	new[112]|new[113]	coref	20-12[138_113]
17-8	2103-2105	of	abstract[112]|abstract[113]	new[112]|new[113]	_	_
17-9	2106-2109	the	abstract[112]|abstract[113]|person[115]	new[112]|new[113]|giv[115]	coref	20-1[0_115]
17-10	2110-2114	four	abstract[112]|abstract[113]|person[115]	new[112]|new[113]|giv[115]	_	_
17-11	2115-2123	activity	abstract[112]|abstract[113]|abstract|person[115]	new[112]|new[113]|giv|giv[115]	coref	28-8
17-12	2124-2131	classes	abstract[112]|abstract[113]|person[115]	new[112]|new[113]|giv[115]	_	_
17-13	2132-2134	is	_	_	_	_
17-14	2135-2141	easily	_	_	_	_
17-15	2142-2153	perceptible	_	_	_	_
17-16	2154-2155	,	_	_	_	_
17-17	2156-2160	with	_	_	_	_
17-18	2161-2164	the	substance[116]	giv[116]	coref	17-33[121_116]
17-19	2165-2169	most	substance[116]	giv[116]	_	_
17-20	2170-2176	active	substance[116]	giv[116]	_	_
17-21	2177-2186	compounds	substance[116]	giv[116]	_	_
17-22	2187-2188	(	_	_	_	_
17-23	2189-2194	class	abstract	new	appos	17-53[126_0]
17-24	2195-2196	A	abstract[118]	new[118]	ana	17-33[0_118]
17-25	2197-2198	,	abstract[118]	new[118]	_	_
17-26	2199-2205	purple	abstract[118]	new[118]	_	_
17-27	2206-2207	)	_	_	_	_
17-28	2208-2214	having	_	_	_	_
17-29	2215-2220	close	_	_	_	_
17-30	2221-2223	to	_	_	_	_
17-31	2224-2228	half	quantity[119]	new[119]	_	_
17-32	2229-2231	of	quantity[119]	new[119]	_	_
17-33	2232-2235	its	quantity[119]|abstract|substance[121]	new[119]|giv|giv[121]	coref|coref	17-48[125_121]|17-48[125_121]
17-34	2236-2245	compounds	quantity[119]|substance[121]	new[119]|giv[121]	_	_
17-35	2246-2247	(	quantity[119]	new[119]	_	_
17-36	2248-2251	~47	quantity[119]|quantity[122]	new[119]|new[122]	coref	17-66[128_122]
17-37	2252-2253	%	quantity[119]|quantity[122]	new[119]|new[122]	_	_
17-38	2254-2255	)	quantity[119]	new[119]	_	_
17-39	2256-2258	in	quantity[119]	new[119]	_	_
17-40	2259-2262	the	quantity[119]|place[123]	new[119]|new[123]	coref	17-62[127_123]
17-41	2263-2272	top-right	quantity[119]|place[123]	new[119]|new[123]	_	_
17-42	2273-2281	quadrant	quantity[119]|place[123]	new[119]|new[123]	_	_
17-43	2282-2284	of	quantity[119]|place[123]	new[119]|new[123]	_	_
17-44	2285-2288	the	quantity[119]|place[123]|abstract[124]	new[119]|new[123]|giv[124]	_	_
17-45	2289-2293	plot	quantity[119]|place[123]|abstract[124]	new[119]|new[123]|giv[124]	_	_
17-46	2294-2295	,	_	_	_	_
17-47	2296-2301	while	_	_	_	_
17-48	2302-2305	the	substance[125]	giv[125]	coref	17-69[131_125]
17-49	2306-2311	least	substance[125]	giv[125]	_	_
17-50	2312-2318	active	substance[125]	giv[125]	_	_
17-51	2319-2328	compounds	substance[125]	giv[125]	_	_
17-52	2329-2330	(	_	_	_	_
17-53	2331-2336	class	abstract[126]	giv[126]	coref	21-4[143_126]
17-54	2337-2338	D	abstract[126]	giv[126]	_	_
17-55	2339-2340	,	_	_	_	_
17-56	2341-2347	orange	_	_	_	_
17-57	2348-2349	)	_	_	_	_
17-58	2350-2353	are	_	_	_	_
17-59	2354-2360	mainly	_	_	_	_
17-60	2361-2373	concentrated	_	_	_	_
17-61	2374-2376	in	_	_	_	_
17-62	2377-2380	the	place[127]	giv[127]	_	_
17-63	2381-2392	bottom-left	place[127]	giv[127]	_	_
17-64	2393-2401	quadrant	place[127]	giv[127]	_	_
17-65	2402-2403	(	_	_	_	_
17-66	2404-2407	~58	quantity[128]	giv[128]	_	_
17-67	2408-2409	%	quantity[128]	giv[128]	_	_
17-68	2410-2412	of	quantity[128]	giv[128]	_	_
17-69	2413-2418	class	quantity[128]|person|substance[131]	giv[128]|new|giv[131]	coref|coref	25-42[0_131]|25-42[0_131]
17-70	2419-2420	D	quantity[128]|person|substance[131]	giv[128]|new|giv[131]	coref	29-40
17-71	2421-2430	compounds	quantity[128]|substance[131]	giv[128]|giv[131]	_	_
17-72	2431-2432	)	_	_	_	_
17-73	2433-2434	,	_	_	_	_
17-74	2435-2437	as	_	_	_	_
17-75	2438-2448	quantified	_	_	_	_
17-76	2449-2451	in	_	_	_	_

#Text=Figure 4
18-1	2452-2458	Figure	abstract[132]	giv[132]	_	_
18-2	2459-2460	4	abstract[132]	giv[132]	_	_

#Text=( right ) .
19-1	2461-2462	(	_	_	_	_
19-2	2463-2468	right	_	_	_	_
19-3	2469-2470	)	_	_	_	_
19-4	2471-2472	.	_	_	_	_

#Text=Classes B ( blue ) and C ( green ) have a more disperse distribution , but show some higher density areas close to the bottom-left corner .
20-1	2473-2480	Classes	person|place[134]	giv|new[134]	coref|coref|coref|coref	21-14[144_0]|29-5[0_134]|21-14[144_0]|29-5[0_134]
20-2	2481-2482	B	place[134]	new[134]	_	_
20-3	2483-2484	(	place[134]	new[134]	_	_
20-4	2485-2489	blue	place[134]	new[134]	_	_
20-5	2490-2491	)	place[134]	new[134]	_	_
20-6	2492-2495	and	place[134]	new[134]	_	_
20-7	2496-2497	C	place[134]|person	new[134]|new	_	_
20-8	2498-2499	(	_	_	_	_
20-9	2500-2505	green	abstract	new	_	_
20-10	2506-2507	)	_	_	_	_
20-11	2508-2512	have	_	_	_	_
20-12	2513-2514	a	abstract[138]	giv[138]	ana	21-1[0_138]
20-13	2515-2519	more	object[137]|abstract[138]	new[137]|giv[138]	_	_
20-14	2520-2528	disperse	object[137]|abstract[138]	new[137]|giv[138]	_	_
20-15	2529-2541	distribution	abstract[138]	giv[138]	_	_
20-16	2542-2543	,	_	_	_	_
20-17	2544-2547	but	_	_	_	_
20-18	2548-2552	show	_	_	_	_
20-19	2553-2557	some	place[140]	new[140]	_	_
20-20	2558-2564	higher	place[140]	new[140]	_	_
20-21	2565-2572	density	abstract|place[140]	new|new[140]	_	_
20-22	2573-2578	areas	place[140]	new[140]	_	_
20-23	2579-2584	close	place[140]	new[140]	_	_
20-24	2585-2587	to	_	_	_	_
20-25	2588-2591	the	place[141]	new[141]	_	_
20-26	2592-2603	bottom-left	place[141]	new[141]	_	_
20-27	2604-2610	corner	place[141]	new[141]	_	_
20-28	2611-2612	.	_	_	_	_

#Text=This indicates that class D , for example , is fundamentally different to the remaining classes from a structural and physicochemical level , and therefore supports the existence of a SAR in the proteasome inhibitors developed in the last 20 years .
21-1	2613-2617	This	abstract	giv	coref	24-17[172_0]
21-2	2618-2627	indicates	_	_	_	_
21-3	2628-2632	that	_	_	_	_
21-4	2633-2638	class	abstract[143]	giv[143]	coref	22-9[151_143]
21-5	2639-2640	D	abstract[143]	giv[143]	_	_
21-6	2641-2642	,	_	_	_	_
21-7	2643-2646	for	_	_	_	_
21-8	2647-2654	example	_	_	_	_
21-9	2655-2656	,	_	_	_	_
21-10	2657-2659	is	_	_	_	_
21-11	2660-2673	fundamentally	_	_	_	_
21-12	2674-2683	different	_	_	_	_
21-13	2684-2686	to	_	_	_	_
21-14	2687-2690	the	person[144]	giv[144]	coref	24-15[170_144]
21-15	2691-2700	remaining	person[144]	giv[144]	_	_
21-16	2701-2708	classes	person[144]	giv[144]	_	_
21-17	2709-2713	from	person[144]	giv[144]	_	_
21-18	2714-2715	a	person[144]|abstract[145]	giv[144]|new[145]	_	_
21-19	2716-2726	structural	person[144]|abstract[145]	giv[144]|new[145]	_	_
21-20	2727-2730	and	person[144]|abstract[145]	giv[144]|new[145]	_	_
21-21	2731-2746	physicochemical	person[144]|abstract[145]	giv[144]|new[145]	_	_
21-22	2747-2752	level	person[144]|abstract[145]	giv[144]|new[145]	_	_
21-23	2753-2754	,	_	_	_	_
21-24	2755-2758	and	_	_	_	_
21-25	2759-2768	therefore	_	_	_	_
21-26	2769-2777	supports	_	_	_	_
21-27	2778-2781	the	abstract[146]	new[146]	_	_
21-28	2782-2791	existence	abstract[146]	new[146]	_	_
21-29	2792-2794	of	abstract[146]	new[146]	_	_
21-30	2795-2796	a	abstract[146]|place[147]	new[146]|new[147]	_	_
21-31	2797-2800	SAR	abstract[146]|place[147]	new[146]|new[147]	_	_
21-32	2801-2803	in	abstract[146]|place[147]	new[146]|new[147]	_	_
21-33	2804-2807	the	abstract[146]|place[147]|abstract[148]	new[146]|new[147]|giv[148]	coref	23-14[161_148]
21-34	2808-2818	proteasome	abstract[146]|place[147]|abstract[148]	new[146]|new[147]|giv[148]	_	_
21-35	2819-2829	inhibitors	abstract[146]|place[147]|abstract[148]	new[146]|new[147]|giv[148]	_	_
21-36	2830-2839	developed	_	_	_	_
21-37	2840-2842	in	_	_	_	_
21-38	2843-2846	the	time[149]	new[149]	_	_
21-39	2847-2851	last	time[149]	new[149]	_	_
21-40	2852-2854	20	time[149]	new[149]	_	_
21-41	2855-2860	years	time[149]	new[149]	_	_
21-42	2861-2862	.	_	_	_	_

#Text=Additionally , no particular cluster was formed with a single class , which means there is no particular location in chemical space ( at least one that is defined by the descriptors that we considered ) which is reserved to one single class .
22-1	2863-2875	Additionally	_	_	_	_
22-2	2876-2877	,	_	_	_	_
22-3	2878-2880	no	object[150]	new[150]	_	_
22-4	2881-2891	particular	object[150]	new[150]	_	_
22-5	2892-2899	cluster	object[150]	new[150]	_	_
22-6	2900-2903	was	_	_	_	_
22-7	2904-2910	formed	_	_	_	_
22-8	2911-2915	with	_	_	_	_
22-9	2916-2917	a	abstract[151]	giv[151]	coref	22-41[157_151]
22-10	2918-2924	single	abstract[151]	giv[151]	_	_
22-11	2925-2930	class	abstract[151]	giv[151]	_	_
22-12	2931-2932	,	_	_	_	_
22-13	2933-2938	which	_	_	_	_
22-14	2939-2944	means	_	_	_	_
22-15	2945-2950	there	_	_	_	_
22-16	2951-2953	is	_	_	_	_
22-17	2954-2956	no	place[152]	new[152]	_	_
22-18	2957-2967	particular	place[152]	new[152]	_	_
22-19	2968-2976	location	place[152]	new[152]	_	_
22-20	2977-2979	in	place[152]	new[152]	_	_
22-21	2980-2988	chemical	place[152]|place[153]	new[152]|giv[153]	coref	24-19[0_153]
22-22	2989-2994	space	place[152]|place[153]	new[152]|giv[153]	_	_
22-23	2995-2996	(	place[152]|place[153]	new[152]|giv[153]	_	_
22-24	2997-2999	at	place[152]|place[153]|quantity[154]	new[152]|giv[153]|new[154]	_	_
22-25	3000-3005	least	place[152]|place[153]|quantity[154]	new[152]|giv[153]|new[154]	_	_
22-26	3006-3009	one	place[152]|place[153]|quantity[154]	new[152]|giv[153]|new[154]	_	_
22-27	3010-3014	that	_	_	_	_
22-28	3015-3017	is	_	_	_	_
22-29	3018-3025	defined	_	_	_	_
22-30	3026-3028	by	_	_	_	_
22-31	3029-3032	the	abstract[155]	giv[155]	_	_
22-32	3033-3044	descriptors	abstract[155]	giv[155]	_	_
22-33	3045-3049	that	_	_	_	_
22-34	3050-3052	we	person	giv	ana	24-3
22-35	3053-3063	considered	_	_	_	_
22-36	3064-3065	)	_	_	_	_
22-37	3066-3071	which	_	_	_	_
22-38	3072-3074	is	_	_	_	_
22-39	3075-3083	reserved	_	_	_	_
22-40	3084-3086	to	_	_	_	_
22-41	3087-3090	one	abstract[157]	giv[157]	coref	25-13[177_157]
22-42	3091-3097	single	abstract[157]	giv[157]	_	_
22-43	3098-3103	class	abstract[157]	giv[157]	_	_
22-44	3104-3105	.	_	_	_	_

#Text=This observation indicates that carrying out compound selection biased for physicochemical similarity to known inhibitors might be a good initial filter to enrich the set of compound candidates with active hits .
23-1	3106-3110	This	abstract[158]	new[158]	coref	30-40[217_158]
23-2	3111-3122	observation	abstract[158]	new[158]	_	_
23-3	3123-3132	indicates	_	_	_	_
23-4	3133-3137	that	_	_	_	_
23-5	3138-3146	carrying	_	_	_	_
23-6	3147-3150	out	_	_	_	_
23-7	3151-3159	compound	abstract[159]	new[159]	_	_
23-8	3160-3169	selection	abstract[159]	new[159]	_	_
23-9	3170-3176	biased	_	_	_	_
23-10	3177-3180	for	_	_	_	_
23-11	3181-3196	physicochemical	abstract[160]	giv[160]	coref	25-7[174_160]
23-12	3197-3207	similarity	abstract[160]	giv[160]	_	_
23-13	3208-3210	to	abstract[160]	giv[160]	_	_
23-14	3211-3216	known	abstract[160]|abstract[161]	giv[160]|giv[161]	_	_
23-15	3217-3227	inhibitors	abstract[160]|abstract[161]	giv[160]|giv[161]	_	_
23-16	3228-3233	might	_	_	_	_
23-17	3234-3236	be	_	_	_	_
23-18	3237-3238	a	object[162]	new[162]	_	_
23-19	3239-3243	good	object[162]	new[162]	_	_
23-20	3244-3251	initial	object[162]	new[162]	_	_
23-21	3252-3258	filter	object[162]	new[162]	_	_
23-22	3259-3261	to	_	_	_	_
23-23	3262-3268	enrich	_	_	_	_
23-24	3269-3272	the	abstract[163]	new[163]	_	_
23-25	3273-3276	set	abstract[163]	new[163]	_	_
23-26	3277-3279	of	abstract[163]	new[163]	_	_
23-27	3280-3288	compound	abstract[163]|abstract|person[165]	new[163]|giv|new[165]	_	_
23-28	3289-3299	candidates	abstract[163]|person[165]	new[163]|new[165]	_	_
23-29	3300-3304	with	abstract[163]|person[165]	new[163]|new[165]	_	_
23-30	3305-3311	active	abstract[163]|person[165]|abstract[166]	new[163]|new[165]|new[166]	_	_
23-31	3312-3316	hits	abstract[163]|person[165]|abstract[166]	new[163]|new[165]|new[166]	_	_
23-32	3317-3318	.	_	_	_	_

#Text=Next , we wanted to investigate what characteristics are responsible for the differences between classes in the chemical space distribution .
24-1	3319-3323	Next	_	_	_	_
24-2	3324-3325	,	_	_	_	_
24-3	3326-3328	we	person	giv	ana	25-16
24-4	3329-3335	wanted	_	_	_	_
24-5	3336-3338	to	_	_	_	_
24-6	3339-3350	investigate	_	_	_	_
24-7	3351-3355	what	_	_	_	_
24-8	3356-3371	characteristics	abstract	new	_	_
24-9	3372-3375	are	_	_	_	_
24-10	3376-3387	responsible	_	_	_	_
24-11	3388-3391	for	_	_	_	_
24-12	3392-3395	the	abstract[169]	new[169]	_	_
24-13	3396-3407	differences	abstract[169]	new[169]	_	_
24-14	3408-3415	between	abstract[169]	new[169]	_	_
24-15	3416-3423	classes	abstract[169]|person[170]	new[169]|giv[170]	coref	25-34[182_170]
24-16	3424-3426	in	abstract[169]|person[170]	new[169]|giv[170]	_	_
24-17	3427-3430	the	abstract[169]|person[170]|abstract[172]	new[169]|giv[170]|giv[172]	coref	29-17[198_172]
24-18	3431-3439	chemical	abstract[169]|person[170]|abstract[172]	new[169]|giv[170]|giv[172]	_	_
24-19	3440-3445	space	abstract[169]|person[170]|place|abstract[172]	new[169]|giv[170]|giv|giv[172]	coref	30-42
24-20	3446-3458	distribution	abstract[169]|person[170]|abstract[172]	new[169]|giv[170]|giv[172]	_	_
24-21	3459-3460	.	_	_	_	_

#Text=Upon applying the Tc to characterize the similarity between Murcko scaffolds within each class , we observed a high diversity in the dataset , not just within each class , but also between the different classes , with most pairs of compounds showing a Tc below 0.5 that represents a considerable dissimilarity (
25-1	3461-3465	Upon	_	_	_	_
25-2	3466-3474	applying	_	_	_	_
25-3	3475-3478	the	abstract[173]	new[173]	coref	25-44[185_173]
25-4	3479-3481	Tc	abstract[173]	new[173]	_	_
25-5	3482-3484	to	_	_	_	_
25-6	3485-3497	characterize	_	_	_	_
25-7	3498-3501	the	abstract[174]	giv[174]	coref	28-10[0_174]
25-8	3502-3512	similarity	abstract[174]	giv[174]	_	_
25-9	3513-3520	between	abstract[174]	giv[174]	_	_
25-10	3521-3527	Murcko	abstract[174]|abstract|object[176]	giv[174]|new|giv[176]	coref|coref	29-1[193_176]|29-1[193_176]
25-11	3528-3537	scaffolds	abstract[174]|object[176]	giv[174]|giv[176]	_	_
25-12	3538-3544	within	abstract[174]|object[176]	giv[174]|giv[176]	_	_
25-13	3545-3549	each	abstract[174]|object[176]|abstract[177]	giv[174]|giv[176]|giv[177]	coref	25-26[181_177]
25-14	3550-3555	class	abstract[174]|object[176]|abstract[177]	giv[174]|giv[176]|giv[177]	_	_
25-15	3556-3557	,	_	_	_	_
25-16	3558-3560	we	person	giv	_	_
25-17	3561-3569	observed	_	_	_	_
25-18	3570-3571	a	abstract[179]	new[179]	_	_
25-19	3572-3576	high	abstract[179]	new[179]	_	_
25-20	3577-3586	diversity	abstract[179]	new[179]	_	_
25-21	3587-3589	in	abstract[179]	new[179]	_	_
25-22	3590-3593	the	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
25-23	3594-3601	dataset	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
25-24	3602-3603	,	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
25-25	3604-3607	not	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
25-26	3608-3612	just	abstract[179]|abstract[180]|abstract[181]	new[179]|giv[180]|giv[181]	coref	29-4[0_181]
25-27	3613-3619	within	abstract[179]|abstract[180]|abstract[181]	new[179]|giv[180]|giv[181]	_	_
25-28	3620-3624	each	abstract[179]|abstract[180]|abstract[181]	new[179]|giv[180]|giv[181]	_	_
25-29	3625-3630	class	abstract[179]|abstract[180]|abstract[181]	new[179]|giv[180]|giv[181]	_	_
25-30	3631-3632	,	_	_	_	_
25-31	3633-3636	but	_	_	_	_
25-32	3637-3641	also	_	_	_	_
25-33	3642-3649	between	_	_	_	_
25-34	3650-3653	the	person[182]	giv[182]	coref	29-27[202_182]
25-35	3654-3663	different	person[182]	giv[182]	_	_
25-36	3664-3671	classes	person[182]	giv[182]	_	_
25-37	3672-3673	,	person[182]	giv[182]	_	_
25-38	3674-3678	with	person[182]	giv[182]	_	_
25-39	3679-3683	most	person[182]|plant[183]	giv[182]|new[183]	_	_
25-40	3684-3689	pairs	person[182]|plant[183]	giv[182]|new[183]	_	_
25-41	3690-3692	of	person[182]|plant[183]	giv[182]|new[183]	_	_
25-42	3693-3702	compounds	person[182]|plant[183]|substance	giv[182]|new[183]|giv	coref	29-35[205_0]
25-43	3703-3710	showing	_	_	_	_
25-44	3711-3712	a	abstract[185]	giv[185]	_	_
25-45	3713-3715	Tc	abstract[185]	giv[185]	_	_
25-46	3716-3721	below	quantity[186]	new[186]	_	_
25-47	3722-3725	0.5	quantity[186]	new[186]	_	_
25-48	3726-3730	that	_	_	_	_
25-49	3731-3741	represents	_	_	_	_
25-50	3742-3743	a	abstract[187]	new[187]	_	_
25-51	3744-3756	considerable	abstract[187]	new[187]	_	_
25-52	3757-3770	dissimilarity	abstract[187]	new[187]	_	_
25-53	3771-3772	(	_	_	_	_

#Text=Figure 5
26-1	3773-3779	Figure	abstract[188]	new[188]	_	_
26-2	3780-3781	5	abstract[188]	new[188]	_	_

#Text=) .
27-1	3782-3783	)	_	_	_	_
27-2	3784-3785	.	_	_	_	_

#Text=Nonetheless a clear trend of correlation between activity and similarity is observed .
28-1	3786-3797	Nonetheless	_	_	_	_
28-2	3798-3799	a	abstract[189]	new[189]	_	_
28-3	3800-3805	clear	abstract[189]	new[189]	_	_
28-4	3806-3811	trend	abstract[189]	new[189]	_	_
28-5	3812-3814	of	abstract[189]	new[189]	_	_
28-6	3815-3826	correlation	abstract[189]|abstract[190]	new[189]|new[190]	_	_
28-7	3827-3834	between	abstract[189]|abstract[190]	new[189]|new[190]	_	_
28-8	3835-3843	activity	abstract[189]|abstract[190]|abstract	new[189]|new[190]|giv	coref	29-36
28-9	3844-3847	and	abstract[189]|abstract[190]	new[189]|new[190]	_	_
28-10	3848-3858	similarity	abstract[189]|abstract[190]|abstract	new[189]|new[190]|giv	_	_
28-11	3859-3861	is	_	_	_	_
28-12	3862-3870	observed	_	_	_	_
28-13	3871-3872	.	_	_	_	_

#Text=The scaffolds of class B differ negligibly from class A , however , class C shows a two-peak distribution which suggests it contains scaffolds similar to both classes A/B , as well as with lower activity compounds ( class D ) .
29-1	3873-3876	The	object[193]	giv[193]	coref	29-24[200_193]
29-2	3877-3886	scaffolds	object[193]	giv[193]	_	_
29-3	3887-3889	of	object[193]	giv[193]	_	_
29-4	3890-3895	class	object[193]|abstract	giv[193]|giv	coref	29-9
29-5	3896-3897	B	place	giv	_	_
29-6	3898-3904	differ	_	_	_	_
29-7	3905-3915	negligibly	_	_	_	_
29-8	3916-3920	from	_	_	_	_
29-9	3921-3926	class	abstract	giv	coref	29-10[197_0]
29-10	3927-3928	A	abstract[197]	giv[197]	coref	29-39[206_197]
29-11	3929-3930	,	abstract[197]	giv[197]	_	_
29-12	3931-3938	however	abstract[197]	giv[197]	_	_
29-13	3939-3940	,	abstract[197]	giv[197]	_	_
29-14	3941-3946	class	abstract[197]	giv[197]	_	_
29-15	3947-3948	C	abstract[197]	giv[197]	_	_
29-16	3949-3954	shows	_	_	_	_
29-17	3955-3956	a	abstract[198]	giv[198]	ana	29-22[0_198]
29-18	3957-3965	two-peak	abstract[198]	giv[198]	_	_
29-19	3966-3978	distribution	abstract[198]	giv[198]	_	_
29-20	3979-3984	which	_	_	_	_
29-21	3985-3993	suggests	_	_	_	_
29-22	3994-3996	it	abstract	giv	_	_
29-23	3997-4005	contains	_	_	_	_
29-24	4006-4015	scaffolds	object[200]|object[201]	giv[200]|giv[201]	coref|coref	30-49[219_200]|30-49[219_200]
29-25	4016-4023	similar	object[200]|object[201]	giv[200]|giv[201]	_	_
29-26	4024-4026	to	object[201]	giv[201]	_	_
29-27	4027-4031	both	object[201]|person[202]	giv[201]|giv[202]	_	_
29-28	4032-4039	classes	object[201]|person[202]	giv[201]|giv[202]	_	_
29-29	4040-4043	A/B	object[201]|person[202]|event	giv[201]|giv[202]|new	_	_
29-30	4044-4045	,	object[201]	giv[201]	_	_
29-31	4046-4048	as	object[201]	giv[201]	_	_
29-32	4049-4053	well	object[201]	giv[201]	_	_
29-33	4054-4056	as	object[201]	giv[201]	_	_
29-34	4057-4061	with	object[201]	giv[201]	_	_
29-35	4062-4067	lower	object[201]|substance[205]	giv[201]|giv[205]	coref	30-52[220_205]
29-36	4068-4076	activity	object[201]|event|substance[205]	giv[201]|giv|giv[205]	coref	31-13
29-37	4077-4086	compounds	object[201]|substance[205]	giv[201]|giv[205]	_	_
29-38	4087-4088	(	_	_	_	_
29-39	4089-4094	class	abstract[206]	giv[206]	ana	30-1[0_206]
29-40	4095-4096	D	abstract[206]|person	giv[206]|giv	coref	31-24
29-41	4097-4098	)	_	_	_	_
29-42	4099-4100	.	_	_	_	_

#Text=This is probably a result of the practical strategies applied in medicinal chemistry where inactive structures are modified/derivatized to meet or better resemble substructures seen among actives , thus creating this transition from A to D. As concluded from the chemical space observation , this also shows that functionalizing scaffolds from more potent compounds ( class A/B ) might be a feasible initial strategy to find new actives .
30-1	4101-4105	This	abstract	giv	ana	30-45
30-2	4106-4108	is	_	_	_	_
30-3	4109-4117	probably	_	_	_	_
30-4	4118-4119	a	_	_	_	_
30-5	4120-4126	result	_	_	_	_
30-6	4127-4129	of	_	_	_	_
30-7	4130-4133	the	abstract[209]	new[209]	_	_
30-8	4134-4143	practical	abstract[209]	new[209]	_	_
30-9	4144-4154	strategies	abstract[209]	new[209]	_	_
30-10	4155-4162	applied	_	_	_	_
30-11	4163-4165	in	_	_	_	_
30-12	4166-4175	medicinal	abstract[210]	new[210]	_	_
30-13	4176-4185	chemistry	abstract[210]	new[210]	_	_
30-14	4186-4191	where	_	_	_	_
30-15	4192-4200	inactive	abstract[211]	new[211]	_	_
30-16	4201-4211	structures	abstract[211]	new[211]	_	_
30-17	4212-4215	are	_	_	_	_
30-18	4216-4236	modified/derivatized	_	_	_	_
30-19	4237-4239	to	_	_	_	_
30-20	4240-4244	meet	_	_	_	_
30-21	4245-4247	or	_	_	_	_
30-22	4248-4254	better	_	_	_	_
30-23	4255-4263	resemble	_	_	_	_
30-24	4264-4277	substructures	object	new	_	_
30-25	4278-4282	seen	_	_	_	_
30-26	4283-4288	among	_	_	_	_
30-27	4289-4296	actives	animal	new	coref	30-67[224_0]
30-28	4297-4298	,	_	_	_	_
30-29	4299-4303	thus	_	_	_	_
30-30	4304-4312	creating	_	_	_	_
30-31	4313-4317	this	event[214]	new[214]	_	_
30-32	4318-4328	transition	event[214]	new[214]	_	_
30-33	4329-4333	from	event[214]	new[214]	_	_
30-34	4334-4335	A	event[214]|person[215]	new[214]|new[215]	_	_
30-35	4336-4338	to	event[214]|person[215]	new[214]|new[215]	_	_
30-36	4339-4341	D.	event[214]|person[215]	new[214]|new[215]	_	_
30-37	4342-4344	As	_	_	_	_
30-38	4345-4354	concluded	_	_	_	_
30-39	4355-4359	from	_	_	_	_
30-40	4360-4363	the	abstract[217]	giv[217]	_	_
30-41	4364-4372	chemical	abstract[217]	giv[217]	_	_
30-42	4373-4378	space	place|abstract[217]	giv|giv[217]	_	_
30-43	4379-4390	observation	abstract[217]	giv[217]	_	_
30-44	4391-4392	,	_	_	_	_
30-45	4393-4397	this	event	giv	coref	30-56
30-46	4398-4402	also	_	_	_	_
30-47	4403-4408	shows	_	_	_	_
30-48	4409-4413	that	_	_	_	_
30-49	4414-4429	functionalizing	abstract[219]	giv[219]	coref	30-61[223_219]
30-50	4430-4439	scaffolds	abstract[219]	giv[219]	_	_
30-51	4440-4444	from	abstract[219]	giv[219]	_	_
30-52	4445-4449	more	abstract[219]|abstract[220]	giv[219]|giv[220]	appos	30-56[222_220]
30-53	4450-4456	potent	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
30-54	4457-4466	compounds	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
30-55	4467-4468	(	_	_	_	_
30-56	4469-4474	class	abstract|abstract[222]	giv|giv[222]	coref|coref	31-22[229_0]|31-22[229_0]
30-57	4475-4478	A/B	abstract[222]	giv[222]	_	_
30-58	4479-4480	)	_	_	_	_
30-59	4481-4486	might	_	_	_	_
30-60	4487-4489	be	_	_	_	_
30-61	4490-4491	a	abstract[223]	giv[223]	coref	31-3[225_223]
30-62	4492-4500	feasible	abstract[223]	giv[223]	_	_
30-63	4501-4508	initial	abstract[223]	giv[223]	_	_
30-64	4509-4517	strategy	abstract[223]	giv[223]	_	_
30-65	4518-4520	to	_	_	_	_
30-66	4521-4525	find	_	_	_	_
30-67	4526-4529	new	animal[224]	giv[224]	_	_
30-68	4530-4537	actives	animal[224]	giv[224]	_	_
30-69	4538-4539	.	_	_	_	_

#Text=However , selected scaffolds should also be sufficiently dissimilar to the lower activity scaffolds , effectively avoiding the right-end tail of the class D ( i. e. , the most similar scaffolds to A , which are still largely inactive ) .
31-1	4540-4547	However	_	_	_	_
31-2	4548-4549	,	_	_	_	_
31-3	4550-4558	selected	object[225]	giv[225]	coref	31-11[227_225]
31-4	4559-4568	scaffolds	object[225]	giv[225]	_	_
31-5	4569-4575	should	_	_	_	_
31-6	4576-4580	also	_	_	_	_
31-7	4581-4583	be	_	_	_	_
31-8	4584-4596	sufficiently	_	_	_	_
31-9	4597-4607	dissimilar	_	_	_	_
31-10	4608-4610	to	_	_	_	_
31-11	4611-4614	the	object[227]	giv[227]	appos	31-29[231_227]
31-12	4615-4620	lower	object[227]	giv[227]	_	_
31-13	4621-4629	activity	abstract|object[227]	giv|giv[227]	_	_
31-14	4630-4639	scaffolds	object[227]	giv[227]	_	_
31-15	4640-4641	,	_	_	_	_
31-16	4642-4653	effectively	_	_	_	_
31-17	4654-4662	avoiding	_	_	_	_
31-18	4663-4666	the	abstract[228]	new[228]	_	_
31-19	4667-4676	right-end	abstract[228]	new[228]	_	_
31-20	4677-4681	tail	abstract[228]	new[228]	_	_
31-21	4682-4684	of	abstract[228]	new[228]	_	_
31-22	4685-4688	the	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
31-23	4689-4694	class	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
31-24	4695-4696	D	abstract[228]|abstract[229]|person	new[228]|giv[229]|giv	_	_
31-25	4697-4698	(	_	_	_	_
31-26	4699-4701	i.	_	_	_	_
31-27	4702-4704	e.	_	_	_	_
31-28	4705-4706	,	_	_	_	_
31-29	4707-4710	the	object[231]	giv[231]	_	_
31-30	4711-4715	most	object[231]	giv[231]	_	_
31-31	4716-4723	similar	object[231]	giv[231]	_	_
31-32	4724-4733	scaffolds	object[231]	giv[231]	_	_
31-33	4734-4736	to	object[231]	giv[231]	_	_
31-34	4737-4738	A	object[231]	giv[231]	_	_
31-35	4739-4740	,	_	_	_	_
31-36	4741-4746	which	_	_	_	_
31-37	4747-4750	are	_	_	_	_
31-38	4751-4756	still	_	_	_	_
31-39	4757-4764	largely	_	_	_	_
31-40	4765-4773	inactive	_	_	_	_
31-41	4774-4775	)	_	_	_	_
31-42	4776-4777	.	_	_	_	_
